Introduction
For any elective medical procedure, the decision to proceed should be grounded in evidence — not marketing language, not anecdote, and not the confident manner of the person selling the procedure. When patients ask whether EVO ICL is safe, they deserve a specific, evidence-based answer that acknowledges both what the clinical data shows and what it does not yet prove.
The short answer is that EVO ICL has an excellent safety profile supported by decades of international clinical experience and a rigorous FDA approval process. Complications are rare, serious complications are very rare, and the most common post-operative concerns are manageable and transient. The evidence also shows that when performed by trained surgeons on appropriately selected candidates, EVO ICL consistently achieves high rates of patient satisfaction and excellent visual outcomes.
But “excellent safety profile” is not the same as “no risk.” Understanding what the risks actually are, how likely they are, and what conditions influence that likelihood is what allows patients to make genuinely informed decisions. This page reviews the evidence thoroughly and honestly.
For information on surgeons recognized for achieving consistently excellent safety outcomes, visit the EVO ICL Awards hub.
Section 1: The Evidence Base — FDA Trial Data and Global Experience
FDA Approval and Clinical Trial Findings
EVO ICL received FDA approval in the United States in March 2022 following a multicenter clinical trial that enrolled patients at multiple U.S. sites and tracked them over three years. The trial demonstrated:
- Visual acuity outcomes: The large majority of trial participants achieved distance visual acuity of 20/20 or better without correction. Patients with high prescriptions (above -6.00 diopters) demonstrated particularly strong outcomes relative to what LASIK can typically achieve at comparable prescription levels.
- Predictability: A high percentage of patients were within 0.50 diopters of their target refraction, indicating excellent precision in lens power calculation.
- Stability: Refraction remained stable over the three-year follow-up period, without the regression seen in some laser correction outcomes.
- Patient satisfaction: Self-reported patient satisfaction rates were consistently high across the trial cohort.
Critically, the FDA approval was supported not only by U.S. trial data but also by a substantial body of international evidence accumulated over more than 20 years of use in Europe, Asia, and Latin America. STAAR Surgical estimates that more than two million EVO ICL procedures have been performed globally. This scale of real-world use is a meaningful signal of the procedure’s clinical durability.
Long-Term Data From International Markets
Countries where the ICL has been available since the 1990s and early 2000s have published long-term outcome data that the U.S. market is only now beginning to generate domestically. These studies — some tracking patients for 10 to 15 years — report:
- Stable refraction without significant lens-related regression
- Preservation of crystalline lens clarity (low cataract rates attributable to the ICL)
- Stable endothelial cell counts that remain within acceptable ranges over time when appropriate candidates are selected
- Low rates of secondary procedures or lens exchange
Endothelial cell loss is one of the most closely scrutinized long-term safety metrics. The corneal endothelium naturally loses cells at approximately 0.5 percent per year across the general population. Early generations of ICL were associated with higher than expected endothelial cell loss in some studies, attributed to the lens design and proximity to the corneal endothelium in eyes with less-than-ideal anterior chamber depth. The EVO generation’s central port and refined design, combined with stricter candidacy criteria, have reduced this concern substantially. Current long-term data does not show accelerated endothelial cell loss in appropriately selected EVO ICL patients.
Section 2: Specific Risks and Their Clinical Frequency
Elevated Intraocular Pressure (IOP)
The most common clinically significant early complication of EVO ICL surgery is a transient spike in intraocular pressure in the 24 hours following surgery. This can result from retained viscoelastic material blocking aqueous drainage, inflammatory debris in the trabecular meshwork, or pupillary block. The central aqueous port in EVO ICL was specifically designed to prevent pupillary block, significantly reducing this mechanism.
When the next-morning IOP check is performed as scheduled, elevated pressure is identified promptly and treated with topical pressure-lowering drops. In the vast majority of cases, this resolves completely within days without lasting consequence. When this visit is skipped and elevated pressure is not identified, the risk of optic nerve damage from sustained ocular hypertension increases significantly — which is why next-morning follow-up is non-negotiable.
Rates of clinically significant IOP elevation in EVO ICL clinical trials are generally reported at less than two to three percent.
Cataract Formation
The natural crystalline lens sits in close proximity to the implanted ICL. If the ICL vault is too low — meaning the gap between the ICL and the natural lens is insufficient — contact between the two can disrupt the metabolic environment of the natural lens and accelerate cataract formation.
This is why vault assessment is central to both pre-operative sizing and post-operative monitoring. In properly sized cases with adequate vault, cataract formation attributable to the ICL is rare. Clinical studies report ICL-related cataract rates well below two percent in appropriately selected and monitored patients. For patients in whom cataract does develop, the ICL is removed at the time of cataract surgery and replaced with an intraocular lens — a straightforward transition that experienced cataract surgeons manage routinely.
Rotation (Toric ICL Specific)
Toric ICL lenses include cylindrical correction to address astigmatism. For this correction to be effective, the lens must be positioned at the correct rotational axis and remain there over time. Rotation of the toric lens — even by a few degrees — can reduce the astigmatic correction and slightly alter the refractive outcome.
Toric ICL rotation rates have been reported at under five percent in clinical studies, with clinically significant rotation (greater than 10 to 15 degrees) less common still. Rotated toric ICLs can typically be realigned in a brief outpatient procedure.
Infection (Endophthalmitis)
Endophthalmitis — infection inside the eye — is the most serious complication of any intraocular surgery. It is extremely rare after EVO ICL, with reported rates below 0.05 percent in published series. The risk is minimized by performing surgery in accredited facilities, using full surgical antisepsis protocols, and prescribing post-operative antibiotics.
When endophthalmitis occurs, it requires urgent intervention with intraocular antibiotics and, in severe cases, vitrectomy. This complication is rare enough that many high-volume EVO ICL surgeons have never personally encountered a case in their own practice.
Retinal Concerns in High Myopes
Patients with high myopia have elongated eyes with greater stretch on peripheral retinal tissue, putting them at higher baseline risk of retinal detachment, lattice degeneration, and other retinal pathology — regardless of any refractive surgery they may have. EVO ICL does not increase this baseline risk, but it also does not eliminate it.
Pre-operative dilated fundus examination is essential for all EVO ICL candidates, and high myopes require particular scrutiny. Any pre-existing retinal pathology should be treated before proceeding with lens implantation. Patients should also be informed that their annual eye exams must include a dilated retinal examination throughout their lives, regardless of the success of their refractive surgery.
Section 3: How Surgeons Influence Safety Outcomes
Patient Selection Is the First Safety Intervention
The most effective risk reduction strategy in EVO ICL is appropriate patient selection. Surgeons who decline to operate on patients with insufficient ACD, low endothelial cell counts, or uncontrolled glaucoma are making the most important safety decisions before entering the operating room. The EVO ICL Awards program recognizes surgeons who apply rigorous candidacy standards consistently.
Sizing Accuracy and Vault Optimization
Complications directly attributable to ICL implantation — elevated IOP from pupillary mechanics, cataract from inadequate vault, and lens exchange for sizing issues — are predominantly related to how well the lens fits the patient’s eye. Surgeons who use modern sizing tools, including anterior segment OCT and ultrasound biomicroscopy, and who validate their sizing nomograms against their own outcomes data, achieve lower complication rates.
For further discussion of surgical evaluation standards, see How EVO ICL Surgeons Are Evaluated for Awards and EVO ICL Surgeon Credentials: What to Look For.
Post-Operative Monitoring Infrastructure
Even a perfectly performed procedure can produce complications that require post-operative management. Practices with structured follow-up protocols, next-morning IOP checks, and ongoing vault monitoring by OCT demonstrate the organizational commitment that separates good surgical practices from excellent ones.
Section 4: What Patients Should Ask About Safety
Before consenting to EVO ICL surgery, patients are entitled to clear, honest answers to the following:
What are your practice’s complication rates? Specifically: lens exchange rates, IOP spike rates, and any infections in your own patient population. Experienced, high-volume surgeons can answer these questions directly.
How do you monitor endothelial cell count over time? Post-operative specular microscopy at appropriate intervals confirms that long-term endothelial health is being tracked.
What is your protocol if my vault is outside target range? Understanding the practice’s decision tree for managing vault concerns — conservative monitoring versus prompt lens exchange — helps set expectations.
How do you manage retinal screening for high myopes? Surgeons who operate on high myopes should have a clear protocol for retinal evaluation before and after surgery, including dilated fundus examination or collaboration with a retinal specialist.
For a comparison of the safety profiles of EVO ICL and LASIK, see EVO ICL vs LASIK: Which Vision Correction Is Right for You?.
Frequently Asked Questions
Has anyone gone blind from EVO ICL? Serious vision-threatening complications are extraordinarily rare. Permanent significant vision loss from properly performed EVO ICL in a well-selected patient is not a recognized common outcome in published clinical literature. The most serious documented complications — severe endophthalmitis, for example — are also rare with modern protocols.
Is EVO ICL safer than LASIK? Both procedures have excellent safety profiles for appropriate patients. EVO ICL preserves corneal tissue and is reversible, which some clinicians and patients regard as inherently lower risk. LASIK carries no intraocular risk since the surgical zone is limited to the corneal surface. The relevant comparison is not which procedure is abstractly safer but which is safer for you, given your specific anatomy. See EVO ICL Candidacy: Who Is a Good Candidate? for a full discussion.
What are the chances I will need a lens exchange? Published rates vary but are generally in the range of two to five percent across large series. Surgeons with refined sizing protocols and careful candidate selection achieve lower rates. Ask your surgeon about their specific experience.
Can the EVO ICL cause glaucoma? EVO ICL does not cause glaucoma, but the procedure can cause transient IOP elevation in the early post-operative period. Patients with pre-existing glaucoma or elevated IOP are not candidates for EVO ICL for this reason.
Next Steps
The evidence supports EVO ICL as a safe and effective procedure for appropriately selected patients, performed by trained surgeons in accredited facilities. Understanding the specific risks, their frequency, and the factors that influence them allows you to evaluate your own risk profile with clarity.
Use the EVO ICL Awards directory to find surgeons who have earned recognition for consistently safe, high-quality EVO ICL outcomes in your geographic area.